148 related articles for article (PubMed ID: 34366886)
21. Serum Adropin Levels Are Reduced in Adult Patients with Nonalcoholic Fatty Liver Disease.
Kutlu O; Altun Ö; Dikker O; Aktaş Ş; Özsoy N; Arman Y; Özgün Çil E; Özcan M; Aydın Yoldemir Ş; Akarsu M; Toprak İD; Kırna K; Kutlu Y; Toprak Z; Eruzun H; Tükek T
Med Princ Pract; 2019; 28(5):463-469. PubMed ID: 30995640
[TBL] [Abstract][Full Text] [Related]
22. Relationship Between Serum Uric Acid-to-Creatinine Ratio and the Risk of Metabolic-Associated Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus.
Xing Y; Chen J; Liu J; Song G; Ma H
Diabetes Metab Syndr Obes; 2022; 15():257-267. PubMed ID: 35140486
[TBL] [Abstract][Full Text] [Related]
23. Novel associations of serum adropin and lipopolysaccharide-binding protein versus lipid profiles in childhood obesity.
Yuan X; Chen R; Ouyang Q; Lin X; Ai Z; Zhang Y; Yang X
J Pediatr Endocrinol Metab; 2020 Feb; 33(2):265-270. PubMed ID: 31953997
[TBL] [Abstract][Full Text] [Related]
24. Circulating levels of adropin and diabetes: a systematic review and meta-analysis of observational studies.
Soltani S; Beigrezaei S; Malekahmadi M; Clark CCT; Abdollahi S
BMC Endocr Disord; 2023 Apr; 23(1):73. PubMed ID: 37029398
[TBL] [Abstract][Full Text] [Related]
25. Serum Adropin Levels in Patients with Rheumatoid Arthritis.
Simac P; Perkovic D; Bozic I; Bilopavlovic N; Martinovic D; Bozic J
Life (Basel); 2022 Jan; 12(2):. PubMed ID: 35207457
[TBL] [Abstract][Full Text] [Related]
26. Serum phospholipid omega-3 polyunsaturated fatty acids and insulin resistance in type 2 diabetes mellitus and non-alcoholic fatty liver disease.
Lou DJ; Zhu QQ; Si XW; Guan LL; You QY; Yu ZM; Zhang AZ
J Diabetes Complications; 2014; 28(5):711-4. PubMed ID: 24927647
[TBL] [Abstract][Full Text] [Related]
27. A STUDY OF THE ASSESSMENT OF SERUM ADROPIN LEVEL AS A RISK FACTOR OF ISCHAEMIC HEART DISEASE IN TYPE 2 DIABETES MELLITUS CASES.
Mansour HK; Makboul K; Elhalawany SH; Ibrahim BE; Marawan DA
Georgian Med News; 2022; (328-329):115-117. PubMed ID: 36318853
[TBL] [Abstract][Full Text] [Related]
28. The Impact of SGLT2 Inhibitor Dapagliflozin on Adropin Serum Levels in Men and Women with Type 2 Diabetes Mellitus and Chronic Heart Failure.
Berezin AA; Obradovic Z; Fushtey IM; Berezina TA; Novikov EV; Schmidbauer L; Lichtenauer M; Berezin AE
Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36830993
[TBL] [Abstract][Full Text] [Related]
29. The association of serum and vitreous adropin concentrations with diabetic retinopathy.
Li S; Sun J; Hu W; Liu Y; Lin D; Duan H; Liu F
Ann Clin Biochem; 2019 Mar; 56(2):253-258. PubMed ID: 30514096
[TBL] [Abstract][Full Text] [Related]
30. Serum metabolomics-based heterogeneities and screening strategy for metabolic dysfunction-associated fatty liver disease (MAFLD).
Shao L; Liu J; Song Y; Yang W; Gong L; Lyu Z; Zhu Q; Fu J; Li J; Shi J
Clin Chim Acta; 2023 Jan; 538():203-210. PubMed ID: 36549641
[TBL] [Abstract][Full Text] [Related]
31. Correlation between Serum Levels of Nitric Oxide and Adropin and Erectile Dysfunction in Males with Nonalcoholic Fatty Liver Disease: An Observational Study.
Ragab A; Fattah AMA; Sayed AR; GamalEl Din SF; Mahmoud Hassan SM; Mohamed AYM; Hamed MA
Reprod Sci; 2024 Apr; ():. PubMed ID: 38691315
[TBL] [Abstract][Full Text] [Related]
32. Pentraxin-3 and adropin as inflammatory markers of early renal damage in type 2 diabetes patients.
Li B; Tian X; Guo S; Zhang M; Li J; Zhai N; Wang H; Zhang Y
Int Urol Nephrol; 2020 Nov; 52(11):2145-2152. PubMed ID: 32661627
[TBL] [Abstract][Full Text] [Related]
33. Distinctive gut microbial dysbiosis between chronic alcoholic fatty liver disease and metabolic-associated fatty liver disease in mice.
Kang K; Sun Y; Pan D; Sang LX; Sun MJ; Li YL; Chang B
Exp Ther Med; 2021 May; 21(5):418. PubMed ID: 33777186
[TBL] [Abstract][Full Text] [Related]
34. Antidiabetic and hypolipidemic effects of adropinin streoptozotocin-induced type 2 diabetic rats.
Akcilar R; Kocak FE; Simsek H; Akcilar A; Bayat Z; Ece E; Kokdasgil H
Bratisl Lek Listy; 2016; 117(2):100-5. PubMed ID: 26830041
[TBL] [Abstract][Full Text] [Related]
35. Adropin's Role in Energy Homeostasis and Metabolic Disorders.
Ali II; D'Souza C; Singh J; Adeghate E
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35955453
[TBL] [Abstract][Full Text] [Related]
36. Enho Mutations Causing Low Adropin: A Possible Pathomechanism of MPO-ANCA Associated Lung Injury.
Gao F; Fang J; Chen F; Wang C; Chen S; Zhang S; Lv X; Zhang J; He Q; Weng S; Liu Q; Lin XH
EBioMedicine; 2016 Jul; 9():324-335. PubMed ID: 27333037
[TBL] [Abstract][Full Text] [Related]
37. Adropin as A Fat-Burning Hormone with Multiple Functions-Review of a Decade of Research.
Jasaszwili M; Billert M; Strowski MZ; Nowak KW; Skrzypski M
Molecules; 2020 Jan; 25(3):. PubMed ID: 32012786
[TBL] [Abstract][Full Text] [Related]
38. Association between serum adropin levels and gestational diabetes mellitus; a case-control study.
Beigi A; Shirzad N; Nikpour F; Nasli Esfahani E; Emamgholipour S; Bandarian F
Gynecol Endocrinol; 2015; 31(12):939-41. PubMed ID: 26376846
[TBL] [Abstract][Full Text] [Related]
39. Promotion of Adropin Expression by Hyperglycemia Is Associated with STAT3 Activation in Diabetic Rats.
Kuo FY; Cheng KC; Li Y; Cheng JT; Tsai CC
Diabetes Metab Syndr Obes; 2020; 13():2269-2277. PubMed ID: 32636661
[TBL] [Abstract][Full Text] [Related]
40. Serum adropin as a predictive biomarker of erectile dysfunction in coronary artery disease patients.
Celik HT; Bilen M; Kazancı F; Yildirim ME; İncebay İB; Erdamar H
Cent European J Urol; 2019; 72(3):302-306. PubMed ID: 31720034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
